계명대학교 의학도서관 Repository

A prospective, multicenter study on the clinical effectiveness of abiraterone in metastatic castration-resistant prostate cancer in Korea: Pre- vs. post-chemotherapy

Metadata Downloads
Author(s)
Seung-Hwan JeongSang Eun YeonSu Youn KimTae Gyun KwonSeong Soo JeonYoung Deuk ChoiDongdeuk KwonByung Ha ChungSung-Hoo HongByung Hoon KimHyo Jin LeeSang Joon ShinWoo Suk ChoiSung Woo ParkTaek Won KangSeok Joong YunJin Seon ChoSee Min ChoiNa-Ri LeeCheol Kwak
Keimyung Author(s)
Kim, Byung Hoon
Department
Dept. of Urology (비뇨의학)
Journal Title
Investig Clin Urol
Issued Date
2023
Volume
64
Issue
5
Keyword
AbirateroneProstate cancerProstate-specific antigenReal-world data
Abstract
Purpose:
The proper treatment sequence for administering abiraterone acetate plus prednisolone (AAP) and chemotherapeutic agents has not yet been elucidated for metastatic castration-resistant prostate cancer (mCRPC). Hence, this study evaluated the effectiveness and safety of AAP in pre- and post-chemotherapy settings using real-world data.

Materials and methods:
This prospective, multicenter, open-label, observational study included 506 patients with mCRPC. Patients were classified according to the timing of chemotherapy into pre- and post-chemotherapy groups. The effectiveness and safety of AAP were compared between the groups; the prostate-specific antigen (PSA) response, PSA progression-free survival, and radiologic progression-free survival were assessed; and adverse drug reactions were recorded.

Results:
Among the included patients, 319 and 187 belonged to the pre- and post-chemotherapy groups, respectively. Risk classification was similar between the two groups. The PSA response was 61.8% in the pre-chemotherapy group and 39.0% in the post-chemotherapy group (p<0.001). The median time to PSA progression (5.00 vs. 2.93 mo, p=0.001) and radiologic progression-free survival (11.84 vs. 9.17 mo, p=0.002) were significantly longer in the pre-chemotherapy group. Chemotherapy status was associated with PSA (hazard ratio [HR] 1.39, 95% confidence interval [CI] 1.09-1.77) and radiologic progression (HR 1.66, 95% CI 1.18-2.33) during AAP treatment. Adverse drug reactions were reported at similar frequencies in both groups.

Conclusions:
In this postmarketing surveillance, AAP benefited patients with mCRPC, especially in settings before chemotherapy was administered, resulting in a high PSA response and longer PSA and radiologic progression-free survival with tolerable adverse drug reactions.
Keimyung Author(s)(Kor)
김병훈
Publisher
School of Medicine (의과대학)
Type
Article
ISSN
2466-054X
Source
https://icurology.org/DOIx.php?id=10.4111/icu.20230128
DOI
10.4111/icu.20230128
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/45225
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Urology (비뇨의학)
Authorize & License
  • Authorize공개
Files in This Item:

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.